Figure 1.
Figure 1. Bv+Bs regimen schedule. Bv, at 1.8 mg/kg IV on day 1 of the 3-week cycle; Bs, at 120 mg/m2 IV on days 2 and 3 of the 3-week cycle; P, peg-filgrastim 6 mg subcutaneous on day 6 of the 3-week cycle; FDG-PET, at baseline and 5 weeks after salvage treatment completion; C, serum CMV-DNA monitoring on day 1 of the 3-week cycle. Moreover, as support prophylactic treatment: methylprednisolone at 200 mg IV on days 1 to 3 of the 3-week cycle, diphenhydramine at 50 mg IV on days 1 to 3 of the 3-week cycle, febuxostat at 80 mg orally on days 1 to 5 of the 3-week cycle (plus hyperhydration); trimethropin-sulfamethoxazole at 960 (160 + 800) mg orally every 12 hours 2 times a week and acyclovir at 800 mg orally daily from the start of Bv+Bs regimen until 1 month after the last cycle. Clinical visits were performed on days 1 to 3 of the 3-week cycle. Routine laboratory tests were performed every 2 weeks.

Bv+Bs regimen schedule. Bv, at 1.8 mg/kg IV on day 1 of the 3-week cycle; Bs, at 120 mg/m2 IV on days 2 and 3 of the 3-week cycle; P, peg-filgrastim 6 mg subcutaneous on day 6 of the 3-week cycle; FDG-PET, at baseline and 5 weeks after salvage treatment completion; C, serum CMV-DNA monitoring on day 1 of the 3-week cycle. Moreover, as support prophylactic treatment: methylprednisolone at 200 mg IV on days 1 to 3 of the 3-week cycle, diphenhydramine at 50 mg IV on days 1 to 3 of the 3-week cycle, febuxostat at 80 mg orally on days 1 to 5 of the 3-week cycle (plus hyperhydration); trimethropin-sulfamethoxazole at 960 (160 + 800) mg orally every 12 hours 2 times a week and acyclovir at 800 mg orally daily from the start of Bv+Bs regimen until 1 month after the last cycle. Clinical visits were performed on days 1 to 3 of the 3-week cycle. Routine laboratory tests were performed every 2 weeks.

Close Modal

or Create an Account

Close Modal
Close Modal